THER (Theralink Technologies) Ending Cash Position: $0.02 Mil (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Theralink Technologies Ending Cash Position?

Theralink Technologies THER -99.00% Ending Cash Position is $0.02 Mil as of Dec. 2023.

Theralink Technologies's Ending Cash Position for the quarter that ended in Dec. 2023 was $0.02 Mil.

Theralink Technologies's quarterly Ending Cash Position increased from Jun. 2023 ($0.03 Mil) to Sep. 2023 ($1.00 Mil) but then declined from Sep. 2023 ($1.00 Mil) to Dec. 2023 ($0.02 Mil).

Theralink Technologies's annual Ending Cash Position increased from Sep. 2021 ($0.31 Mil) to Sep. 2022 ($0.39 Mil) and increased from Sep. 2022 ($0.39 Mil) to Sep. 2023 ($1.00 Mil).

Theralink Technologies Ending Cash Position Related Terms

Theralink Technologies Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Theralink Technologies's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theralink Technologies Ending Cash Position Chart

Theralink Technologies Annual Data
Trend Feb14 Feb15 Dec16 Dec17 Dec18 Dec19 Sep20 Sep21 Sep22 Sep23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 1.78 0.31 0.39 1.00

Theralink Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.13 0.21 0.03 1.00 0.02

Theralink Technologies Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Theralink Technologies's Ending Cash Position for the fiscal year that ended in Sep. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.393+0.604
=1.00

Theralink Technologies's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.998+-0.974
=0.02

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.02 Mil mean?
Theralink Technologies (THER) has a Ending Cash Position of $0.02 Mil as of Dec. 2023. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Theralink Technologies and its competitors.
Is Theralink Technologies' Ending Cash Position too high?
Theralink Technologies' current Ending Cash Position is $0.02 Mil.
How does Theralink Technologies' Ending Cash Position compare to AXIM and ISCO?
Theralink Technologies' Ending Cash Position of $0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Theralink Technologies and its competitors. Theralink Technologies's current Ending Cash Position is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralink Technologies stock overvalued right now?
Theralink Technologies (THER) has a current Ending Cash Position of $0.02 Mil. The current Ending Cash Position is $0.02 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Theralink Technologies (THER), the current Ending Cash Position is $0.02 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Theralink Technologies Business Description

Address 15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401
Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.